Prospective observational study investigating clinical impact by using electronic patient-reported outcomes (ePRO) on the management of adverse events of chemotherapy

Prospective observational study investigating clinical impact by using electronic patient-reported outcomes (ePRO) on the management of adverse events of chemotherapy - Management of adverse events by using ePRO

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042955

Enrollment

Registered

2021-01-12

Start date

2020-05-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Pathologically diagnosed as breast cancer (2) Receiving systemic anticancer pharmacotherapy (e.g., cytotoxic anticancer agents, molecularly targeted drugs, and immune checkpoint inhibitors) for breast cancer (3) Capable of using electronic devices (4) Written consent for the study personally obtained from the subject

Exclusion criteria

Exclusion criteria: (1) Difficulty in using electronic devices (2) Receiving hormone therapy only

Design outcomes

Primary

Measure	Time frame
Percentage of unscheduled visits	—

Secondary

Measure	Time frame
Compliance with inputting adverse events into the ePRO system	—

Countries

Japan

Contacts

Public ContactTetsuhiko Taira

Sagara Hospital Department of Oncology

ttaira-tt@sagara.or.jp099-224-1800

Outcome results